Concord Biotech Limited (BOM:543960)
1,200.20
+33.40 (2.86%)
At close: Jun 3, 2026
Concord Biotech Revenue
In the fiscal year ending March 31, 2026, Concord Biotech had annual revenue of 10.55B INR, down -12.10%. Concord Biotech had revenue of 3.26B in the quarter ending March 31, 2026, a decrease of -24.15%.
Revenue
10.55B
Revenue Growth
-12.10%
P/S Ratio
11.92
Revenue / Employee
6.71M
Employees
1,571
Market Cap
125.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 10.55B | -1.45B | -12.10% |
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
Concord Biotech News
- 2 days ago - Concord Biotech Transcript: Q4 25/26 - Transcripts
- 2 days ago - Concord Biotech Quarterly report: Q4 2026 - Filings
- 2 days ago - Concord Biotech Slides: Q4 2026 - Filings
- 3 months ago - Concord Biotech Transcript: Q3 25/26 - Transcripts
- 3 months ago - Concord Biotech Quarterly report: Q3 2026 - Filings
- 3 months ago - Concord Biotech Slides: Q3 2026 - Filings
- 7 months ago - Concord Biotech Transcript: Q2 25/26 - Transcripts
- 7 months ago - Concord Biotech Quarterly report: Q2 2026 - Filings